Quadramet
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Samarium [153Sm] lexidronam pentasodium
- Made by
- CIS bio international
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan. The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | CIS bio international |
|---|---|
| Active substance | Samarium [153Sm] lexidronam pentasodium |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V10BX02 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 1998-02-04 |
| Last updated by the regulator | 2025-11-06 |
| EMA product number | EMEA/H/C/000150 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).